Latest News and Press Releases

Doheny Eye Institute named Yuhua Zhang, PhD, chairholder of the Carolyn and Chuck Miller Endowed Chair for Vision Research.

Dublin, April 16, 2026 (GLOBE NEWSWIRE) -- The "Thyroid Eye Disease Treatment Market (2026 Edition)" report has been added to ResearchAndMarkets.com's offering.This report provides a complete...

ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...

PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative...

VG801 shows encouraging preliminary efficacy in the ongoing Phase 1/2 trial, with consistent functional improvements in best-corrected visual acuity (BCVA) and Virtual Reality Visual Test (VRVT),...

ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical...

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...

Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Thyroid Eye Disease Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035" has been added to ResearchAndMarkets.com's...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. aloneMultiple milestones...

ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritisPrivosegtor is advancing...